Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6074
Abstract: 6074 Background: Selpercatinib is a first-in-class, CNS active, highly selective, and potent RET kinase inhibitor which has demonstrated durable antitumor activity in patients (pts) with RET altered thyroid cancer and is approved in multiple countries… read more here.
Keywords: therapy; response; thyroid cancer; prior therapy ... See more keywords
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0657
Abstract: Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with… read more here.
Keywords: mutant medullary; ret mutant; phase; inhibitor ... See more keywords